Welcome to the new morningstar.co.uk! Learn more about the changes and how our new features help your investing success.

Horizon Discovery Signs Agreement With US Immune-Oncology Firm

LONDON (Alliance News) - Gene modification company Horizon Discovery Group PLC said on Monday ...

Alliance News 12 February, 2018 | 1:46PM
Email Form

LONDON (Alliance News) - Gene modification company Horizon Discovery Group PLC said on Monday it has signed a non-exclusive license agreement with an unnamed US immune-oncology company.

Under the agreement's terms, Horizon will licence a novel cell line engineering technology to its US partner as well as non-exclusive rights to the group's Heltiron transposon gene editing technology for an undisclosed payment.

Transposons are pieces of DNA that can move from one site to another within one genome which can contribute to the formation of new genes.

The technology will go towards modifying one of Horizon's manufacturing cell line to generate an intermediate, which will allow for rapid development of a wide range of cell lines designed to produce specific antibodies.

"Innovation and leverage of our capabilities, of which both intermediate cell line engineering and transposon technologies are key examples, are important parts of our strategy as we continue to develop novel ways to address the key challenges facing our customers. This agreement demonstrates the impact of this approach and the value of licenses to our novel technologies, and we anticipate this becoming a significant additional revenue stream for the group going forward," said Chief Executive Officer Darrin Disley.

Shares in Horizon Discovery Group were up 2.7% at 190.00 pence on Monday.

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2018 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Horizon Discovery Group PLC 163.81 GBX -1.91 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites